Pandorum Technologies has closed an $18 million Series B financing round to advance the clinical development of its disease-modifying, tunable, exosome-based therapies, including Kuragenx, while scaling global manufacturing and expanding operations across the United States, Japan, and the Middle East.

The round was led by Protons Corporate, with participation from Galentic Pharma, marquee investor Ashish Kacholia, Noblevast Advisory Avinya Fund, Burman family, and others. Bandana Kankani, advisor and investor at Pandorum, guided the transaction, optimizing the alignment between the investment architecture and company’s value creation.

Founded by Dr. Tuhin Bhowmick and Arun Chandru, Pandorum’s proprietary platform combines biology, engineering, and computation to develop tunable, regenerative exosome therapies that reprogram pathological tissue states, like inflammation and fibrosis, toward functional recovery. “Congratulations to our team for this achievement. Regenerative medicine, particularly for corneal blindness, is a global necessity that knows no borders,” Chandru stated.

The clinical translation efforts are led by globally recognized clinicians, including Dr. Virender Singh Sangwan (Dr. Shroff’s Charity Eye Hospital, New Delhi), Dr. Shigeru Kinoshita (Kyoto Prefectural University of Medicine, Kyoto), and Dr. Ramez Haddadin and Dr. Satish Nadig (Northwestern Medicine, Chicago).

Pandorum has implemented a globally distributed manufacturing strategy, including a CDMO partnership with AGC Biologics (Italy) for the U.S. and European markets, and a strategic collaboration with Nucelion Therapeutics (India), a subsidiary of Bharat Biotech, to support supply across the Asia-Pacific region. The company is also exploring potential partnerships in the Middle East.

“Just like the Ship of Theseus, the human body is constantly being rebuilt. Pandorum focuses on restoring biological memory, redefining regenerative medicine at its core,” said Dr. Bhowmick, CEO of Pandorum. “Our approach treats tissue health, disease, and degeneration as a navigational challenge within an information-constrained biological landscape. This funding would enable us to translate breakthrough science into programmable, disease-modifying therapies, beginning with single-tissue applications and scaling to multi-tissue repair, aligned with Pandorum’s vision- to heal fast and age slow.”

Pandorum’s primary focus is on ocular surface diseases, such as Stevens–Johnson Syndrome and Neurotrophic Keratitis, for which Kuragenx has received U.S. Food and Drug Administration Orphan Drug Designation. In addition to ophthalmology, it is expanding its tunable platform to address systemic conditions, including inflammatory and degenerative diseases affecting the lung, liver, and nervous systems.

Pandorum Technologies is a biotechnology company focused on tissue engineering and regenerative medicine. The company operates research facilities in India and the United States.